This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and Spain.
Many patients with MM are cured by common therapies. Some patients may not respond to treatment (refractory). Others may lose response over time (relapsed). bb2121 is a new therapy for MM which causes the immune system to attack and kill tumor cells. It is important to investigate the effects of new therapies for non-responsive MM.
This trial is evaluating the safety and effectiveness of bb2121 in patients with relapsed and refractory MM. The main outcomes measured will be response to treatment, side effects, and survival.
Who are they looking for?
This trial is recruiting 181 patients. To participate, all individuals must have detectable MM.
Patients who have experienced brain problems associated with MM may not participate. Patients who are currently treated with medicines that interfere with the immune system may not participate. Patients with infections, other cancers in the past 5 years also cannot participate.
How will it work
Participants will be divided into two groups. Patients in group 1 will have been treated with at least 3 therapies for MM before the trial. Patients in group 2 will have been treated with one therapy. Patients in both groups will receive bb2121 therapy. Overall response, whether a patient responds fully and side effects of therapy will all be measured. Patients will be followed up for a minimum of 5 years.